RBII to Contract with Producers/Processors in MMJ States to License and Market Cannophen™, THC Products
SANDUSKY, Ohio, June 11, 2018 (GLOBE NEWSWIRE) -- (via OTC PR WIRE) – Rising Biosciences, Inc. (OTC:RBII) (“RBII” “the Company”), a research and development company focusing on oral and topical pharmaceuticals with strict standards set forward by the pharmaceutical compounding industry, is pleased to announce that it is currently working with producers and processors in California, Arizona and Ohio to produce its products under licensing agreements with a target for end of September 2018 for the Company’s first products to hit dispensary shelves.
Rising Biosciences is also pleased to announce that FINRA has approved its name and ticker change and the Company is currently recognized by OTC Markets and otherwise as Rising Biosciences, Inc. under ticker RBII.
As well, the Board has voted to move forward with steps to file a registration with the SEC to become a fully reporting company. We are currently identifying legal counsel and auditing firm toward QB while growing operations to meet listing qualifications for one of the major exchanges. The Company is also interviewing a digital marketing firm to assist with public relations and marketing of its revolutionary product line.
CEO Robert Weber announces that Rising Biosciences is now in the final stages of FDA testing of its TSW Pain Cream products and have entered a contract with Reed Tech Life Sciences , a Medical Device, Prescription Drug OTC and Biologics Regulatory Professional Firm.
“They will be handling our FDA drug listing requirements, and obtaining our NDC, which stands for ‘national drug code’ for our pain cream products. Having this NDC will allow us to have physicians write prescriptions for the pain creams. In line with president trumps initiative to stop opiate abuse, also making it payable by Medicaid, Medicare and private insurance companies. We will also be offering a version of the creams for the retail market as well.”
Weber adds, “Also, our new stem cell cream has now gone into production, and will be available for sale by the end of this quarter. This product will first be available on Amazon. Our clinical strength peptide complex exceeded our expectations on Amazon, and we expect to be similarly pleased with customer reception of our stem cell cream.”
$RSII on Twitter for LIVE company updates! www.twitter.com/risingindiausa
Forward-Looking Statements: Certain statements in this news release may contain forward-looking information within the meaning of Rule 175 under the Securities Act of 1933 and Rule 3b-6 under the Securities Exchange Act of 1934, and are subject to the safe harbor created by those rules. All statements, other than statements of fact, included in this release, including, without limitation, statements regarding potential future plans and objectives of the company, are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Technical complications, which may arise, could prevent the prompt implementation of any strategically significant plan(s) outlined above. The Company undertakes no duty to revise or update any forward- looking statements to reflect events or circumstances after the date of this release.
CONTACT INFO: For Investor Inquiries: IR@risingbiosciences.com
